Detection and phenotyping of circulating tumor cells in high-risk localized prostate cancer

Sumanta K. Pal, Miaoling He, Timothy Wilson, Xueli Liu, Keqiang Zhang, Courtney Carmichael, Alejandra Torres, Sonya Hernandez, Clayton Lau, Neeraj Agarwal, Mark Kawachi, Yun Yen, Jeremy O. Jones

研究成果: 雜誌貢獻文章

28 引文 (Scopus)

摘要

Background In this study, we aimed to determine the feasibility of identifying CTCs in patients with HRLPC, using a modified isolation procedure using the CellSearch (Veridex) platform, and to assess the expression of stem cell and epithelial-mesenchymal transition (EMT) markers on the CTCs. Patients and Methods Thirty-five patients with HRLPC who had chosen prostatectomy for definitive management were prospectively identified. After obtaining consent, four 30-mL blood draws were performed, 2 before surgery and 2 after surgery. The CTC-containing fraction was Ficoll-purified and transferred to a CellSave (Veridex) tube containing dilution buffer before standard enumeration using the CellSearch system. Loss of E-cadherin expression, a marker of EMT, and CD133, a putative prostate cancer stem cell marker, were characterized using the open channel of the CellSearch platform. CTC fragments were also enumerated. Results Using the modified methodology, CTCs were detectable in 49% of patients before surgery. Although no correlation between CTC count and biochemical recurrence (BR) was observed, the percentages of CD133 and E-cadherin-positive CTC fragments were associated with BR at 1 year. Conclusion Our results suggest that further research into the development of CTCs as prognostic biomarkers in HRLPC is warranted.
原文英語
頁(從 - 到)130-136
頁數7
期刊Clinical Genitourinary Cancer
13
發行號2
DOIs
出版狀態已發佈 - 四月 1 2015
對外發佈Yes

指紋

Circulating Neoplastic Cells
Prostatic Neoplasms
Epithelial-Mesenchymal Transition
Cadherins
Recurrence
Ficoll
Neoplastic Stem Cells
Prostatectomy
Buffers
Stem Cells
Biomarkers
Research

ASJC Scopus subject areas

  • Oncology
  • Urology

引用此文

Pal, S. K., He, M., Wilson, T., Liu, X., Zhang, K., Carmichael, C., ... Jones, J. O. (2015). Detection and phenotyping of circulating tumor cells in high-risk localized prostate cancer. Clinical Genitourinary Cancer, 13(2), 130-136. https://doi.org/10.1016/j.clgc.2014.08.014

Detection and phenotyping of circulating tumor cells in high-risk localized prostate cancer. / Pal, Sumanta K.; He, Miaoling; Wilson, Timothy; Liu, Xueli; Zhang, Keqiang; Carmichael, Courtney; Torres, Alejandra; Hernandez, Sonya; Lau, Clayton; Agarwal, Neeraj; Kawachi, Mark; Yen, Yun; Jones, Jeremy O.

於: Clinical Genitourinary Cancer, 卷 13, 編號 2, 01.04.2015, p. 130-136.

研究成果: 雜誌貢獻文章

Pal, SK, He, M, Wilson, T, Liu, X, Zhang, K, Carmichael, C, Torres, A, Hernandez, S, Lau, C, Agarwal, N, Kawachi, M, Yen, Y & Jones, JO 2015, 'Detection and phenotyping of circulating tumor cells in high-risk localized prostate cancer', Clinical Genitourinary Cancer, 卷 13, 編號 2, 頁 130-136. https://doi.org/10.1016/j.clgc.2014.08.014
Pal, Sumanta K. ; He, Miaoling ; Wilson, Timothy ; Liu, Xueli ; Zhang, Keqiang ; Carmichael, Courtney ; Torres, Alejandra ; Hernandez, Sonya ; Lau, Clayton ; Agarwal, Neeraj ; Kawachi, Mark ; Yen, Yun ; Jones, Jeremy O. / Detection and phenotyping of circulating tumor cells in high-risk localized prostate cancer. 於: Clinical Genitourinary Cancer. 2015 ; 卷 13, 編號 2. 頁 130-136.
@article{1a26b26d997c41c79daf66cb71b2996e,
title = "Detection and phenotyping of circulating tumor cells in high-risk localized prostate cancer",
abstract = "Background In this study, we aimed to determine the feasibility of identifying CTCs in patients with HRLPC, using a modified isolation procedure using the CellSearch (Veridex) platform, and to assess the expression of stem cell and epithelial-mesenchymal transition (EMT) markers on the CTCs. Patients and Methods Thirty-five patients with HRLPC who had chosen prostatectomy for definitive management were prospectively identified. After obtaining consent, four 30-mL blood draws were performed, 2 before surgery and 2 after surgery. The CTC-containing fraction was Ficoll-purified and transferred to a CellSave (Veridex) tube containing dilution buffer before standard enumeration using the CellSearch system. Loss of E-cadherin expression, a marker of EMT, and CD133, a putative prostate cancer stem cell marker, were characterized using the open channel of the CellSearch platform. CTC fragments were also enumerated. Results Using the modified methodology, CTCs were detectable in 49{\%} of patients before surgery. Although no correlation between CTC count and biochemical recurrence (BR) was observed, the percentages of CD133 and E-cadherin-positive CTC fragments were associated with BR at 1 year. Conclusion Our results suggest that further research into the development of CTCs as prognostic biomarkers in HRLPC is warranted.",
keywords = "CD133, CellSearch, EMT, Fragment, Stem cell",
author = "Pal, {Sumanta K.} and Miaoling He and Timothy Wilson and Xueli Liu and Keqiang Zhang and Courtney Carmichael and Alejandra Torres and Sonya Hernandez and Clayton Lau and Neeraj Agarwal and Mark Kawachi and Yun Yen and Jones, {Jeremy O.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.clgc.2014.08.014",
language = "English",
volume = "13",
pages = "130--136",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Detection and phenotyping of circulating tumor cells in high-risk localized prostate cancer

AU - Pal, Sumanta K.

AU - He, Miaoling

AU - Wilson, Timothy

AU - Liu, Xueli

AU - Zhang, Keqiang

AU - Carmichael, Courtney

AU - Torres, Alejandra

AU - Hernandez, Sonya

AU - Lau, Clayton

AU - Agarwal, Neeraj

AU - Kawachi, Mark

AU - Yen, Yun

AU - Jones, Jeremy O.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Background In this study, we aimed to determine the feasibility of identifying CTCs in patients with HRLPC, using a modified isolation procedure using the CellSearch (Veridex) platform, and to assess the expression of stem cell and epithelial-mesenchymal transition (EMT) markers on the CTCs. Patients and Methods Thirty-five patients with HRLPC who had chosen prostatectomy for definitive management were prospectively identified. After obtaining consent, four 30-mL blood draws were performed, 2 before surgery and 2 after surgery. The CTC-containing fraction was Ficoll-purified and transferred to a CellSave (Veridex) tube containing dilution buffer before standard enumeration using the CellSearch system. Loss of E-cadherin expression, a marker of EMT, and CD133, a putative prostate cancer stem cell marker, were characterized using the open channel of the CellSearch platform. CTC fragments were also enumerated. Results Using the modified methodology, CTCs were detectable in 49% of patients before surgery. Although no correlation between CTC count and biochemical recurrence (BR) was observed, the percentages of CD133 and E-cadherin-positive CTC fragments were associated with BR at 1 year. Conclusion Our results suggest that further research into the development of CTCs as prognostic biomarkers in HRLPC is warranted.

AB - Background In this study, we aimed to determine the feasibility of identifying CTCs in patients with HRLPC, using a modified isolation procedure using the CellSearch (Veridex) platform, and to assess the expression of stem cell and epithelial-mesenchymal transition (EMT) markers on the CTCs. Patients and Methods Thirty-five patients with HRLPC who had chosen prostatectomy for definitive management were prospectively identified. After obtaining consent, four 30-mL blood draws were performed, 2 before surgery and 2 after surgery. The CTC-containing fraction was Ficoll-purified and transferred to a CellSave (Veridex) tube containing dilution buffer before standard enumeration using the CellSearch system. Loss of E-cadherin expression, a marker of EMT, and CD133, a putative prostate cancer stem cell marker, were characterized using the open channel of the CellSearch platform. CTC fragments were also enumerated. Results Using the modified methodology, CTCs were detectable in 49% of patients before surgery. Although no correlation between CTC count and biochemical recurrence (BR) was observed, the percentages of CD133 and E-cadherin-positive CTC fragments were associated with BR at 1 year. Conclusion Our results suggest that further research into the development of CTCs as prognostic biomarkers in HRLPC is warranted.

KW - CD133

KW - CellSearch

KW - EMT

KW - Fragment

KW - Stem cell

UR - http://www.scopus.com/inward/record.url?scp=84924551706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924551706&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2014.08.014

DO - 10.1016/j.clgc.2014.08.014

M3 - Article

C2 - 25450039

AN - SCOPUS:84924551706

VL - 13

SP - 130

EP - 136

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 2

ER -